Newcells Biotech is pleased to announce that it has appointed Dr Frank Armstrong to its Board as a Non-executive Director. “Attracting an executive of Frank’s proven track-record and expertise is another significant
Retinitis pigmentosa (RP) is a group of degenerative disorders of the retina, caused by mutations in one of more than 60 genes, including the genes for making rhodopsin, pre-mRNA processing factors and usherin. The genes
Antibacterial resistance is an ever-increasing concern for today’s society. As more bacterial strains become resistant to greater numbers of antibiotics, we could see modern-day healthcare rewind back to the mid-1940’s, when antibiotics
Newcells Biotech are one of three Phase I contract winners of a challenge-led competition that funds collaborations between industry, academics and SMEs to solve business and scientific ‘Challenges’. The NC3Rs challenge (named ImmuLiver), sponsored by Sanofi
2018 has been a significant year for Newcells Biotech. We have secured substantial investment, launched new, ground-breaking products, attended global events and expanded our every growing team. Here are some of our defining moments
International Trade Mission – December 2018 Newcells Biotech CEO, Dr Mike Nicholds, and CSO, Prof Lyle Armstrong, are delighted to be taking part in a global trade mission hosted by the Department for International Trade and partially funded by the Northern Powerhouse. Dr Nicholds and Prof Armstrong will travel to Greater
Congress Round-Up The International Congress on in vitro Toxicology (ESTIV2018) organised by the European Society of Toxicology was held in Berlin this October 2018. This year marks its 20th meeting, with the general theme of new approach methodologies
Stevenage Bio Event Professor Lyle Armstrong will be attending a special event on Wednesday 24th October at the Stevenage Bioscience Catalyst where he will give an innovative presentation on ‘Induced Pluripotent Stem Cells: A Powerful
Retinal organoids are becoming a powerful tool in the process of drug discovery, as recently shown by researchers at Newcells Biotech and Newcastle University in a study led by Professor Majlinda Lako
Newcells Biotech has announced that Dr Colin Brown, one of the world’s leading experts on drug transport and drug toxicity in kidney will join the company as Director of ADMET Technology. The company has also
Dr Colin Brown will be presenting two posters at 22nd North American Meeting of the International Society for the Study of Xenobiotics.
Newcells Biotech has secured a £2 million investment from NVM Private Equity and Northstar Ventures to support its ambitious growth plans.
